Guggenheim:重申Danaher(DHR.US)评级,由买入调整至买入评级,目标价由250.00美元调整至250.00美元。丹纳赫(DHR.US)公司简介:丹纳赫公司从事专业、医疗、工业和商业产品和服务的设计、制造和营销。它通过以下部门运作:生物技术,生命科学,诊断,环境和应用解决方案。生物技术部门包括生物处理和发现以及医疗业务,并提供一系列工具,消耗品和服务。生命科学部门提供一系列仪器和...
Source LinkGuggenheim:重申Danaher(DHR.US)评级,由买入调整至买入评级,目标价由250.00美元调整至250.00美元。丹纳赫(DHR.US)公司简介:丹纳赫公司从事专业、医疗、工业和商业产品和服务的设计、制造和营销。它通过以下部门运作:生物技术,生命科学,诊断,环境和应用解决方案。生物技术部门包括生物处理和发现以及医疗业务,并提供一系列工具,消耗品和服务。生命科学部门提供一系列仪器和...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.